Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Eddingpharm Raises $24 Million in Series B

publication date: Sep 22, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eddingpharm (Cayman) Inc., a Shanghai firm that seeks to in-license and then market Western drugs to hospitals in China, has closed a $24 million Series B financing. The company said it would use the new capital to in-license additional drugs, co-develop prescription drugs for sale in China, and seek M&A opportunities. More details....

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...